Medium materiality6/10
Acadia Pharmaceuticals (ACAD) PT Raised to $14.50 at BofA Securities
Why it may matterVerify against the original reporting
sell
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
BofA Securities raises ACAD's target to $14.50, but the current price is $26.01, placing the setup firmly bearish as the target remains well below market price.
- Target $14.50 vs price $26.01; bearish setup.
Key facts
- 01
Target: $14.5
- 02
Posted price: $26.01
- 03
Analyst firm: Raymond James
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.